Ubrelvy

Active Ingredient(s): Ubrogepant
FDA Approved: * December 23, 2019
Pharm Company: * ALLERGAN
Category: Migraine / Tension Headache

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Ubrelvy Overview

Ubrogepant, sold under the trade name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.[1] It is not indicated for the preventive treatment of migraine.[1] It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.[1] The most common side effects are nausea, tir...

Read more Ubrelvy Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ubrogepant

Recent Ubrelvy Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ubrogepant

Tablet: 100mg, 10mg, 50mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Ubrelvy: (2 results)

Sorted by National Drug Code

0023-6498 Ubrelvy 50 mg Oral Tablet by Allergan, Inc.
0023-6501 Ubrelvy 100 mg Oral Tablet by Allergan, Inc.

Other drugs which contain Ubrogepant or a similar ingredient: (1 result)

UBROGEPANT